SecBot SecBot

JBIO

Jade Biosciences, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001798749 Biotech & Drug Discovery
$14.50 −0.09 (−0.62%)
Oct 26 4:00 PM ET · prev $14.59
Market cap
$948.2M
Small cap
Consensus
Buy
94% Buy or better · 17 analysts
Median target
$47.00
+224% · range $40.00–77.00
Next earnings
Nov 11
in 15 days · EPS est. −$0.79
1 year
+42.3%
from $10.19 · Oct 27
30 days
+1.0%
from $14.35
52-week range
$8.95–26.85
−46% from high · low Nov 6
Avg volume 20D
920.1K
shares / day
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
3
Q2 2026 13F · 0 exits
Filing reports
12
analyzed by SecBot
SecBot read BULLISH 3 reports · 90 days
Balance 0 bearish · 2 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 3/3 ·Next Earnings date, Nov 11, 2026
Strongest NEUTRAL Jade Biosciences announced preclinical data for JADE301, an anti-IFN-β monoclonal antibody for…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 37 added (3 new), 8 trimmed or exited. Largest new: Adage Capital Partners Gp, L.L.C $42.5M, Polar Capital Holdings $41.0M.

  • AnalystsBULLISH

    16 of 17 rate it Buy or better. Every target is above the price.

  • TrendDOWNTREND

    15% below its 50-day average.

Who's buying

13F· Q2 2026
3
new positions
0
exits
$99.8M
in new stakes
FundMoveSharesValue
FMR LLCADD9,126,877$202.8M
STATE STREET CORPDOUBLED2,335,285$51.9M
ADAGE CAPITAL PARTNERS GP, L.L.C.NEW1,910,812$42.5M
Polar Capital Holdings PlcNEW1,846,982$41.0M
JPMORGAN CHASE & CODOUBLED1,475,079$32.6M
BAKER BROS. ADVISORS LPTRIM1,230,426$27.3M
CITADEL ADVISORS LLCDOUBLED929,407$20.7M
BALYASNY ASSET MANAGEMENT L.P.DOUBLED878,726$19.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

17 analysts
Buy 94% rate it Buy or better
Strong Buy8Buy8Hold1Sell0Strong Sell0
12-month targets · 8 analysts

Price is below the lowest target. Median implies +224%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 27, 2026🔒 Fresh data, subscribers only
REITERATE
REITERATE
Oct 1, 2026Wedbush
REITERATE
REITERATEOutperform
Oct 1, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 11, 2026Wedbush
MAINTAIN
MAINTAINOutperform
Aug 10, 2026BTIG
MAINTAIN
MAINTAINBuy
Jun 15, 2026UBS
INITIATE
INITIATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jun 25, 2026
Eisner Mark
Director
AWARD47,675 sh
Jun 9, 2026
Fairmount Funds Management LLC
Director
AWARD34,843 sh
Jun 9, 2026
Lavelle Erin
Director
AWARD34,843 sh
Jun 9, 2026
DOBMEIER ERIC
Director
AWARD34,843 sh
Jun 9, 2026
Klein Lawrence Otto
Director
AWARD34,843 sh
Jun 9, 2026
CAIN CHRISTOPHER W.
Director
AWARD34,843 sh
Feb 12, 2026
King Andrew James
See Remarks
AWARD41,250 sh
Feb 12, 2026
King Andrew James
See Remarks
AWARD247,500 sh

Earnings setup

Estimates
Nov 11
reports in 15 days
−$0.79
EPS estimate, this quarter
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.79-$0.79–-$0.79-39.1%$0.00
Next Q-$0.81-$0.81–-$0.81-34.3%$0.00
Current FY-$2.93-$2.93–-$2.93-28.5%$0.00
Next FY-$2.66-$2.66–-$2.66-16.8%$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 SEC
Jade Biosciences announced preclinical data for JADE301, an anti-IFN-β monoclonal antibody for dermatomyositis…
8-K — Impact 4/10
Sep 1, 2026 Other
Jade Biosciences to Participate in Upcoming Conferences
SAN FRANCISCO and VANCOUVER, British Columbia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences,
Aug 10, 2026 SEC
Jade Biosciences reported Q2 2026 results with net loss of -$0.76 per share (vs -$0.86 YoY), a pre-revenue…
8-K — Impact 7/10
Aug 10, 2026 SEC
Jade Biosciences reported Q2 2026 financial results with a net loss of $55.8M, wider than the $32.1M loss in Q2 2025…
PRESS-RELEASE — Impact 7/10
Jun 30, 2026 Inst.
FMR LLC — ADD
9,126,877 shares ($202.8M)
Jun 30, 2026 Inst.
STATE STREET CORP — DOUBLED
2,335,285 shares ($51.9M)
Jun 25, 2026 Insider
Eisner Mark was granted 47,675 shares
Director
Jun 9, 2026 Insider
Fairmount Funds Management LLC was granted 34,843 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
JBIO Q3 2026 Earnings After Market Close — 2026-11-11
Recent
Sep 1, 2026
Press release
Jade Biosciences to Participate in Upcoming Conferences
SAN FRANCISCO and VANCOUVER, British Columbia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a…
Aug 14, 2026
Short interest
Short Interest: JBIO up 11% to 9.7M shares
Settlement 2026-08-14 | Days to cover: 10.15 | ≈15.17% of shares outstanding (est.)
Aug 11, 2026
Earnings date
JBIO Q2 2026 Earnings Before Market Open — 2026-08-11
Aug 10, 2026
Earnings
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
SAN FRANCISCO and VANCOUVER, British Columbia, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a…
Jul 31, 2026
Short interest
Short Interest: JBIO up 15% to 8.7M shares
Settlement 2026-07-31 | Days to cover: 11.50 | ≈17.61% of shares outstanding (est.)

SecBot reports

12 filings · 5 press releases · 3 bullish · 6 bearish · 3 neutral
All JBIO filing & press-release reports (17)